Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for alleged violations of securities laws, specifically related to misleading statements and fraudulent activities [1][4]. Group 1: Lawsuit Details - The lawsuit is initiated by the Schall Law Firm, focusing on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Nutex securities between August 8, 2024, and August 14, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Nutex - The complaint alleges that Nutex made false and misleading statements regarding its financial health and operations [4]. - Nutex is accused of engaging in a scheme with HaloMD to defraud insurance companies, leading to unsustainable revenue [4]. - The company reportedly overstated its internal controls and failed to accurately calculate stock-based compensation obligations, resulting in materially misleading public statements [4].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased LifeMD, Inc. (NASDAQ: LFMD) securities between May 7, 2025, and August 5, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Allegations - The complaint asserts that LifeMD's management materially overstated the company's competitive position [2]. - It is claimed that the company was reckless in raising its 2025 guidance without properly accounting for increasing customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - As a result, statements made by the defendants about LifeMD's business operations and prospects were materially false and misleading [2]. Financial Impact - On August 5, 2025, LifeMD revised its full-year 2025 guidance for revenue and adjusted EBITDA due to "temporary challenges" in its RexMD business, which led to a significant stock price drop of $5.31 per share, or 44.8%, closing at $6.53 on August 6, 2025 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by October 27, 2025, and can remain absent class members if they choose not to participate [4]. Company Background - Robbins LLP has been a leader in shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [5].

Core Viewpoint - Berger Montague PC is investigating claims against Fiserv, Inc. following a class action lawsuit alleging that the company overstated its growth by not disclosing issues with its Clover payment platform [1][3]. Group 1: Lawsuit Details - The class action lawsuit claims that Fiserv and certain executives failed to disclose that Clover's revenue growth was artificially inflated due to the forced transition of merchants from the legacy Payeezy platform [3]. - Investors became aware of Fiserv's true financial situation after the company lowered its 2025 organic growth projections on July 23, 2025, leading to a significant decline in share price [4]. Group 2: Investor Information - Investors who purchased Fiserv securities between July 24, 2024, and July 22, 2025, have until September 22, 2025, to seek appointment as lead plaintiff representatives [2][5].

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in KinderCare Learning Companies, Inc. ("KinderCare Learning Companies, Inc." or the "Company") (NYSE: KLC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of KinderCare Learning Companies, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all purchasers of KinderCare common stock in or traceable to the Company’s Octobe ...

Core Viewpoint - Investors in Snap Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements made by the company regarding its advertising growth and earnings potential [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit claims that from April 29, 2025, to August 5, 2025, Snap's management failed to disclose critical information, including that their optimistic reports on advertising growth were not reflective of actual performance [2]. - It is alleged that Snap was facing significant execution errors, contradicting the company's claims of a lack of visibility due to macroeconomic conditions [2]. - The positive statements made by Snap's management regarding the company's business and prospects were deemed materially misleading and lacked a reasonable basis during the relevant period [2]. Participation Information - Investors who suffered losses related to Snap Inc. are encouraged to participate in the ongoing securities fraud lawsuit, with a lead plaintiff deadline set for October 20, 2025 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Sensus Healthcare, Inc. and its officers or directors [1]. Financial Performance - On August 7, 2025, Sensus reported a GAAP earnings-per-share of -$0.06 for Q2 2025, missing estimates by $0.09 [3]. - The company's revenue for the second quarter was $7.3 million, reflecting a year-over-year decline of 20.7% and missing estimates by $2 million [3]. - The revenue decline was primarily attributed to a lower number of units sold to a large customer, although there was some growth in recurring revenue from Fair Deal Agreements [3]. Stock Market Reaction - Following the financial results announcement, Sensus's stock price dropped by $1.89 per share, or 35.32%, closing at $3.46 per share on August 8, 2025 [4].

NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in PubMatic, Inc. ("PubMatic, Inc." or the "Company") (NASDAQ: PUBM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PubMatic, Inc. investors who were adversely affected by alleged securities fraud between February 27, 2025 and August 11, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pubmatic-inc-lawsui ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors, leading to a significant stock price decline [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, resulting in a 38% drop in stock price from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, caused another 38% decline in stock price from $12.79 to $7.95 per share [6].

Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with concerns regarding the sustainability of its sales growth driven by temporary trade inventory loading rather than genuine consumer demand [1][2]. Group 1: Company Overview - BellRing Brands operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. - The company reported that Premier Protein achieved an all-time high in household penetration, indicating strong demand and growth across all channels due to distribution expansion and promotional activities [2]. Group 2: Sales Growth Concerns - The sales growth during the relevant period may not be sustainable, as it could have been artificially inflated by temporary trade inventory loading at key retailers [2]. - On May 5, 2025, BellRing disclosed that several key retailers reduced their weeks of supply, which would negatively impact growth in Q3 2025 [3]. Group 3: Stock Performance - Following the May 5 announcement, BellRing's stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [3]. - On August 4, 2025, the company reported disappointing quarterly consumption of Premier Protein RTD Shakes, leading to a further decline in stock price by $17.46, or nearly 33%, from $53.64 to $36.18 per share [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased PubMatic, Inc. securities between February 27, 2025, and August 11, 2025, due to alleged misleading statements by the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that PubMatic made false and misleading statements regarding its business operations, particularly related to a significant demand side platform buyer shifting clients to a new platform, which negatively impacted PubMatic's ad spend and revenue [5]. - Investors who purchased PubMatic securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as Rosen Law Firm has achieved significant settlements in the past, including over $438 million for investors in 2019 [4]. - A lead plaintiff is needed to represent the class, and interested parties must move the Court by October 20, 2025, to serve in this capacity [3]. Group 3: Next Steps for Investors - To join the class action, investors can visit the provided link or contact Rosen Law Firm directly for more information [3][6]. - It is important to note that no class has been certified yet, and investors are not represented by counsel unless they retain one [7].